Noelia López1, Ángel Gil-de-Miguel2, Raquel Pascual-García2, Ruth Gil-Prieto2. 1. a Epidemiology and Public Health Program , University Rey Juan Carlos , Alcorcón , Madrid , Spain. 2. b Department of Preventive Medicine and Public Health , University Rey Juan Carlos , Alcorcón , Madrid , Spain.
Abstract
BACKGROUND: Approximately 40,000 new cases of anal cancer and 26,000 new cases of penile cancer occurred in 2012 worldwide. Human Papillomavirus (HPV) infection is responsible for 88.3% and 33.0% of these cancers, respectively. The aim of this study was to describe the hospital burden associated with malignant neoplasm (MN) and in situ carcinoma (ISC) in the anus and penis in Spain from 2009 to 2013. METHODS: This observational, retrospective study used discharge information obtained from the national surveillance system for hospital data, Conjunto Mínimo Básico de Datos, provided by the Ministry of Health. RESULTS: We found 3,668 hospitalizations due to MN and ISC in the anus for both genders, and more than 55% of these hospitalizations occurred in men and were associated with a lower median age of hospitalization (p < 0.001), higher average length of hospital stay (ALOS) (p = 0.0032), higher hospitalization costs (p < 0.001) and higher hospitalization rate (2.141 per 100,000 males aged > 14 y old and 1.604 per 100,000 women aged > 14 y old, p < 0.001) than in women. During the same period, 4,156 hospitalizations due to MN and ISC of the penis were registered. The hospitalization rate was 4.320 per 100,000 males aged > 14 y old. The hospitalization rate due to MN and ISC in the anus in males increased significantly during this period (p = 0.048). CONCLUSION: Our study provides relevant information about the hospital burden of anal and penile MN and ISC in Spain. This information could be useful for cost effectiveness analysis of universal HPV vaccination and for future HPV vaccination impact monitoring in Spain, and for other countries of similar socioeconomic status.
BACKGROUND: Approximately 40,000 new cases of anal cancer and 26,000 new cases of penile cancer occurred in 2012 worldwide. Human Papillomavirus (HPV) infection is responsible for 88.3% and 33.0% of these cancers, respectively. The aim of this study was to describe the hospital burden associated with malignant neoplasm (MN) and in situ carcinoma (ISC) in the anus and penis in Spain from 2009 to 2013. METHODS: This observational, retrospective study used discharge information obtained from the national surveillance system for hospital data, Conjunto Mínimo Básico de Datos, provided by the Ministry of Health. RESULTS: We found 3,668 hospitalizations due to MN and ISC in the anus for both genders, and more than 55% of these hospitalizations occurred in men and were associated with a lower median age of hospitalization (p < 0.001), higher average length of hospital stay (ALOS) (p = 0.0032), higher hospitalization costs (p < 0.001) and higher hospitalization rate (2.141 per 100,000 males aged > 14 y old and 1.604 per 100,000 women aged > 14 y old, p < 0.001) than in women. During the same period, 4,156 hospitalizations due to MN and ISC of the penis were registered. The hospitalization rate was 4.320 per 100,000 males aged > 14 y old. The hospitalization rate due to MN and ISC in the anus in males increased significantly during this period (p = 0.048). CONCLUSION: Our study provides relevant information about the hospital burden of anal and penile MN and ISC in Spain. This information could be useful for cost effectiveness analysis of universal HPV vaccination and for future HPV vaccination impact monitoring in Spain, and for other countries of similar socioeconomic status.
Entities:
Keywords:
HPV; anus; hospitalizations; in situ carcinoma; malignant neoplasia; penis
Authors: Anna R Giuliano; Joel M Palefsky; Stephen Goldstone; Edson D Moreira; Mary E Penny; Carlos Aranda; Eftyhia Vardas; Harald Moi; Heiko Jessen; Richard Hillman; Yen-Hwa Chang; Daron Ferris; Danielle Rouleau; Janine Bryan; J Brooke Marshall; Scott Vuocolo; Eliav Barr; David Radley; Richard M Haupt; Dalya Guris Journal: N Engl J Med Date: 2011-02-03 Impact factor: 91.245
Authors: Ruth Gil-Prieto; Pablo Viguera Ester; Alejandro Álvaro-Meca; María San Martín Rodríguez; Ángel Gil De Miguel Journal: Hum Vaccin Immunother Date: 2012-02-01 Impact factor: 3.452
Authors: Joel M Palefsky; Anna R Giuliano; Stephen Goldstone; Edson D Moreira; Carlos Aranda; Heiko Jessen; Richard Hillman; Daron Ferris; Francois Coutlee; Mark H Stoler; J Brooke Marshall; David Radley; Scott Vuocolo; Richard M Haupt; Dalya Guris; Elizabeth I O Garner Journal: N Engl J Med Date: 2011-10-27 Impact factor: 91.245
Authors: Laia Alemany; Maëlle Saunier; Isabel Alvarado-Cabrero; Beatriz Quirós; Jorge Salmeron; Hai-Rim Shin; Edyta C Pirog; Núria Guimerà; Gustavo Hernandez-Suarez; Ana Felix; Omar Clavero; Belen Lloveras; Elena Kasamatsu; Marc T Goodman; Brenda Y Hernandez; Jan Laco; Leopoldo Tinoco; Daan T Geraets; Charles F Lynch; Vaclav Mandys; Mario Poljak; Robert Jach; Josep Verge; Christine Clavel; Cathy Ndiaye; JoEllen Klaustermeier; Antonio Cubilla; Xavier Castellsagué; Ignacio G Bravo; Michael Pawlita; William G Quint; Nubia Muñoz; Francesc X Bosch; Silvia de Sanjosé Journal: Int J Cancer Date: 2014-05-30 Impact factor: 7.396
Authors: Lisa G Johnson; Margaret M Madeleine; Laura M Newcomer; Stephen M Schwartz; Janet R Daling Journal: Cancer Date: 2004-07-15 Impact factor: 6.860
Authors: Jesús De La Fuente; Juan José Hernandez Aguado; María San Martín; Paula Ramirez Boix; Sergio Cedillo Gómez; Noelia López Journal: Hum Vaccin Immunother Date: 2019-02-20 Impact factor: 3.452